BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26541643)

  • 1. Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors.
    Schneider JL; Kolitsopoulos F; Corley DA
    Aliment Pharmacol Ther; 2016 Jan; 43(1):73-82. PubMed ID: 26541643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea.
    Seo SI; Park CH; You SC; Kim JY; Lee KJ; Kim J; Kim Y; Yoo JJ; Seo WW; Lee HS; Shin WG
    Gut; 2021 Nov; 70(11):2066-2075. PubMed ID: 33975868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton Pump Inhibitor Use and Risk of Gastric, Colorectal, Liver, and Pancreatic Cancers in a Community-Based Population.
    Lee JK; Merchant SA; Schneider JL; Jensen CD; Fireman BH; Quesenberry CP; Corley DA
    Am J Gastroenterol; 2020 May; 115(5):706-715. PubMed ID: 32205645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for
    Cheung KS; Chan EW; Wong AYS; Chen L; Wong ICK; Leung WK
    Gut; 2018 Jan; 67(1):28-35. PubMed ID: 29089382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
    Brusselaers N; Wahlin K; Engstrand L; Lagergren J
    BMJ Open; 2017 Oct; 7(10):e017739. PubMed ID: 29084798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised clinical trial: high-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers.
    Chen CC; Lee JY; Fang YJ; Hsu SJ; Han ML; Tseng PH; Liou JM; Hu FC; Lin TL; Wu MS; Wang HP; Lin JT
    Aliment Pharmacol Ther; 2012 Apr; 35(8):894-903. PubMed ID: 22369682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
    Tsai CF; Chen MH; Wang YP; Chu CJ; Huang YH; Lin HC; Hou MC; Lee FY; Su TP; Lu CL
    Gastroenterology; 2017 Jan; 152(1):134-141. PubMed ID: 27639806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
    Leonard CE; Bilker WB; Brensinger CM; Flockhart DA; Freeman CP; Kasner SE; Kimmel SE; Hennessy S
    Stroke; 2015 Mar; 46(3):722-31. PubMed ID: 25657176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea.
    Kim YS; Kim SJ; Yoon JH; Suk KT; Kim JB; Kim DJ; Kim DY; Min HJ; Park SH; Shin WG; Kim KH; Kim HY; Baik GH
    Aliment Pharmacol Ther; 2011 Nov; 34(9):1098-105. PubMed ID: 21923713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pantoprazole: a proton pump inhibitor with oral and intravenous formulations.
    Devault KR
    Expert Rev Gastroenterol Hepatol; 2007 Dec; 1(2):197-205. PubMed ID: 19072410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection.
    McNicholl AG; Linares PM; Nyssen OP; Calvet X; Gisbert JP
    Aliment Pharmacol Ther; 2012 Sep; 36(5):414-25. PubMed ID: 22803691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-Varying Use of Proton Pump Inhibitors and Cognitive Impairment and Dementia: A Real-World Analysis from Germany.
    Ahn N; Wawro N; Baumeister SE; Nolde M; Gerlach R; Tauscher M; Günter A; Güntner F; Rückert-Eheberg IM; Meisinger C; Linseisen J
    Drugs Aging; 2023 Jul; 40(7):653-663. PubMed ID: 37178361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication.
    Villoria A; Garcia P; Calvet X; Gisbert JP; Vergara M
    Aliment Pharmacol Ther; 2008 Oct; 28(7):868-77. PubMed ID: 18644011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil.
    Schaier M; Scholl C; Scharpf D; Hug F; Bönisch-Schmidt S; Dikow R; Schmitt WH; Schwenger V; Zeier M; Sommerer C
    Rheumatology (Oxford); 2010 Nov; 49(11):2061-7. PubMed ID: 20671023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective administration method of intravenous proton pump inhibitor: a novel testing using a BRAVO catheterless pH monitoring system.
    Kım KJ; Park MI; Park SJ; Cho SW; Moon W; Kim GM; Kim WM
    Turk J Gastroenterol; 2011 Dec; 22(6):575-81. PubMed ID: 22287401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden.
    Brusselaers N; Sadr-Azodi O; Engstrand L
    J Gastroenterol; 2020 Apr; 55(4):453-461. PubMed ID: 31811561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period.
    Haastrup PF; Paulsen MS; Christensen RD; Søndergaard J; Hansen JM; Jarbøl DE
    Aliment Pharmacol Ther; 2016 Jul; 44(1):78-87. PubMed ID: 27137875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
    Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of lysosomal enzyme activities by proton pump inhibitors.
    Liu W; Baker SS; Trinidad J; Burlingame AL; Baker RD; Forte JG; Virtuoso LP; Egilmez NK; Zhu L
    J Gastroenterol; 2013 Dec; 48(12):1343-52. PubMed ID: 23478938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
    Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
    Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.